+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05919264

Study of FOG-001 for Treatment of Locally Advanced or Metastatic Solid Tumors and Familial Adenomatous Polyposis

Led by Parabilis Medicines, Inc. · Updated on 2026-10-07

619

Participants Needed

33

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating FOG-001, a study drug, in participants with locally advanced or metastatic solid tumors, including those with familial adenomatous polyposis FAP. This Phase 12 trial aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of FOG-001, given alone or combined with other anticancer agents, in tumors with Wnt pathway activating mutations or related conditions. FOG-001 is administered either intravenously or subcutaneously in continuous 28-day cycles. It is studied as monotherapy and in combination with drugs such as mFOLFOX-6, Nivolumab, Trifluridinetipiracil, and Bevacizumab. The trial includes dose escalation and dose expansion phases across multiple subgroups, including various solid tumors, colorectal cancer types, hepatocellular carcinoma, desmoid tumors, metastatic prostate cancer, and FAP. Participants will undergo regular assessments including safety monitoring for adverse events, tumor biopsies, imaging evaluations using RECIST criteria, and blood tests to measure drug levels and response markers such as PSA in prostate cancer. The study tracks outcomes like response rates, disease control, progression-free survival, and pharmacokinetic parameters over approximately 10 months. Safety and tolerability are closely observed during dose escalation and expansion periods.

CONDITIONS

Brief Title

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Research Team

C

Clinical Trial Inquiries

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here